Molecular Partners :Understanding the huge potential of the DARPin platform




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Molecular Partners :Understanding the huge potential of the DARPin platform
Released on: June 08, 2012. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this episode of PharmaTelevision News Review, filmed in Amsterdam at BioEurope Spring 2012, Fintan Walton talks to Christian Zahnd, CEO of Molecular Partners.
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, filmed in Amsterdam at BioEurope Spring 2012, Fintan Walton talks to Christian Zahnd, CEO of Molecular Partners.
In this interview, filmed in Amsterdam at BioEurope Spring 2012, Fintan talks to Christian Zahnd from Molecular Partners
Christian Zahnd
Molecular Partners
Molecular Partners
Molecular Partners is a privately owned biopharmaceutical company, located in Zurich, Switzerland, that is pioneering the development of a novel class of targeted protein therapeutics termed DARPins. DARPins are as target specific and potent as monoclonal antibodies. Yet, being small proteins, they overcome the known limitations of conventional protein-based therapeutic approaches. We address real medical needs and develop cutting-edge medicine based on innovative DARPin products. The DARPin platform has rapidly generated a differentiated pipeline of drug candidates. The most advanced DARPin is MP0112, an inhibitor of VEGF, which is in Phase I/IIa development. Further products are in research and preclinical development. We balance our internal drug development efforts with strategic alliances with renowned pharmaceutical companies. Molecular Partners is backed by a very strong international syndicate of institutional and corporate investors.